Saccharomyces cerevisiae (yeast) has been genetically modified to express CEA protein and employed as a heat-killed immune-stimulating, therapeutic cancer vaccine (GI-6207). A previous phase I study with GI-6207 demonstrated safety, bio-marker stabilization and enhanced immune response in some patients. CEA is over-expressed in multiple malignancies, including medullary thyroid cancer (MTC). The recently FDA-approved therapies for metastatic MTC (vandetanib, cabozantinib) come with significant toxicity and are reserved for symptomatic/progressive disease. There is a large population of asymptomatic MTC patients with small tumor burden and/or disease that remains indolent. The standard management of these patients is observation. Preliminary data suggest that tumor growth rate (as measured by CEA and calcitonin) is a quantifiable variable within a 3-6 month time-frame. Retrospective data from prostate cancer studies suggest that vaccines can alter growth rates within 3-4 months. We hypothesize that GI-6207 can alter tumor growth rate in this asymptomatic, indolent MTC patient population, and potentially impact long term outcome. A phase 2 study at the NCI will evaluate the effect of GI-6207 on calcitonin growth rates in metastatic MTC. 34 patients with minimally symptomatic, radiographically-evaluable, metastatic MTC will be randomized 1:1. Arm A will receive vaccine for a year from the time of enrollment. Arm B will receive the same schedule vaccine after a period of 6 months of surveillance. GI-6207 will be administered subcutaneously at 4 sites at 10 yeast units/site, every 2 weeks for 7 visits (day 1, 15, 29, 43, 57, 71, 85), then monthly up to 1 year of treatment. The primary end point will compare the effect of GI-6207 on calcitonin growth rate kinetics between the vaccine and surveillance arms at 6 months. Secondary end points include immunologic responses (CEA-specific T cells, effector/regulatory T-cell ratio, natural killer cells, myeloid derived suppressor cells) objective responses, time to progression, and changes in CEA kinetics. If this trial can prospectively demonstrate that vaccines can alter tumor growth rate, and such changes are associated with clinical outcomes, then changes in tumor growth rate may become a clinical metric to evaluate vaccine efficacy in MTC and other populations. The study opened in March of 2013 and 8 patients have been enrolled.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011280-04
Application #
8763429
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2013
Total Cost
$50,338
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Madan, Ravi A; Gulley, James L; Kantoff, Philip W (2013) Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J 19:50-8
Huang, Jianping; Jochems, Caroline; Talaie, Tara et al. (2012) Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood 120:3030-8
Madan, Ravi A; Schwaab, Thomas; Gulley, James L (2012) Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. J Natl Compr Canc Netw 10:1505-12
Madan, Ravi A; Aragon-Ching, Jeanny B; Gulley, James L et al. (2011) From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines 10:743-53
Gulley, J L; Madan, R A; Schlom, J (2011) Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 18:e150-7
Stein, Wilfred D; Gulley, James L; Schlom, Jeff et al. (2011) Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17:907-17
Vergati, Matteo; Cereda, Vittore; Madan, Ravi A et al. (2011) Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother 60:197-206
Gulley, James L; Arlen, Philip M; Madan, Ravi A et al. (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59:663-74
Rotow, Julia; Gameiro, Sofia R; Madan, Ravi A et al. (2010) Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci 3:116-22
Madan, Ravi A; Mohebtash, Mahsa; Schlom, Jeffrey et al. (2010) Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther 10:19-28

Showing the most recent 10 out of 11 publications